Gary B. Nickol

Array ( [id] => 19127240 [patent_doc_number] => 20240132593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => ANTI-VISTA ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/276417 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 82133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18276417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432521 [patent_doc_number] => 20240301019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => RECOMBINANT EOMES RESTORES ANTI-CANCER ACTIVITY OF IMMUNE CELLS [patent_app_type] => utility [patent_app_number] => 18/262648 [patent_app_country] => US [patent_app_date] => 2022-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10781 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18262648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19656973 [patent_doc_number] => 20240424038 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => BLUE-GREEN ALGAE-CONTAINING TABLET [patent_app_type] => utility [patent_app_number] => 18/273796 [patent_app_country] => US [patent_app_date] => 2022-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2798 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18273796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464199 [patent_doc_number] => 20240317868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => ANTI-IL1RAP ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/275616 [patent_app_country] => US [patent_app_date] => 2022-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51021 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18275616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17997873 [patent_doc_number] => 11498967 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-15 [patent_title] => CD80 variant immunomodulatory proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 17/591499 [patent_app_country] => US [patent_app_date] => 2022-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 13 [patent_no_of_words] => 79399 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17591499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20193601 [patent_doc_number] => 20250270311 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-28 [patent_title] => METHOD AND MEANS FOR MODULATING B-CELL MEDIATED IMMUNE RESPONSES [patent_app_type] => utility [patent_app_number] => 18/274624 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31846 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18274624 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19125802 [patent_doc_number] => 20240131155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => T CELLS FOR USE IN THERAPY [patent_app_type] => utility [patent_app_number] => 18/273468 [patent_app_country] => US [patent_app_date] => 2022-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29018 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18273468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17627264 [patent_doc_number] => 20220162279 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => COMBINATION IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/577973 [patent_app_country] => US [patent_app_date] => 2022-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36300 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17577973 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20824952 [patent_doc_number] => 12678494 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-07-14 [patent_title] => Immunogenic composition comprising multivalent [patent_app_type] => utility [patent_app_number] => 18/271946 [patent_app_country] => US [patent_app_date] => 2022-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5643 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18271946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987823 [patent_doc_number] => 20240059792 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => SIALIDASE-HER2-ANTIBODY FUSION PROTEINS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/260383 [patent_app_country] => US [patent_app_date] => 2022-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40158 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -67 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18260383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20320130 [patent_doc_number] => 20250332218 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-30 [patent_title] => FORMULATION CONTAINING SOLUBLE GP130 DIMER AND METHOD FOR USING SAME [patent_app_type] => utility [patent_app_number] => 18/270139 [patent_app_country] => US [patent_app_date] => 2021-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18270139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19497671 [patent_doc_number] => 20240336689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => TREATMENT OF CANCERS WITH AN ANTIBODY THAT BINDS LGR5 AND EGFR [patent_app_type] => utility [patent_app_number] => 18/257528 [patent_app_country] => US [patent_app_date] => 2021-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18257528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19875845 [patent_doc_number] => 20250108102 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-03 [patent_title] => NOVEL FRAGMENTED CRS PEPTIDE EXHIBITING IMMUNE ENHANCEMENT ACTIVITY, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/266540 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15848 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18266540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18971958 [patent_doc_number] => 20240052050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/257804 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22227 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -53 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18257804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18877470 [patent_doc_number] => 20240000839 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => BCMA-TARGETED CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 18/255514 [patent_app_country] => US [patent_app_date] => 2021-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18107 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879426 [patent_doc_number] => 20240002795 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => T CELL RECEPTORS SPECIFIC FOR A MUTANT FORM OF THE RET ONCOGENE AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/038071 [patent_app_country] => US [patent_app_date] => 2021-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14890 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18038071 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18863317 [patent_doc_number] => 20230417753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => METHODS AND KITS FOR CLASSIFYING SOLID CANCER-AFFLICTED PATIENTS BASED ON RELB LABELLING [patent_app_type] => utility [patent_app_number] => 18/036500 [patent_app_country] => US [patent_app_date] => 2021-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16729 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18036500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19479481 [patent_doc_number] => 20240327523 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-03 [patent_title] => DEPLETING MONOCLONAL ANTIBODIES AGAINST NATURAL KILLER CELLS [patent_app_type] => utility [patent_app_number] => 18/034234 [patent_app_country] => US [patent_app_date] => 2021-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9790 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18034234 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19172526 [patent_doc_number] => 20240158500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => CD160 Binding Domain [patent_app_type] => utility [patent_app_number] => 18/550739 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18550739 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170896 [patent_doc_number] => 20240156870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => ANTI-EGFR SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 18/550715 [patent_app_country] => US [patent_app_date] => 2021-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18550715 [rel_patent_id] =>[rel_patent_doc_number] =>)